Antegrade vs. Retrograde Ureteral Stenting for Malignant Obstruction: Clinical Outcomes of a Single-Stage Approach
Abstract
Aim: Malignant ureteral obstruction (MUO) is a serious complication of advanced-stage malignancies, associated with limited life expectancy and lacking standardized management guidelines. This study aims to compare the technical and clinical success rates, as well as the complication profiles, of retrograde ureteral stenting (RUS) and antegrade ureteral stenting (AUS)—including its single- and multi-stage subtypes—in the treatment of MUO.
Materials and Methods: In this retrospective single-center study, 127 patients (155 procedures) who underwent ureteral stenting for MUO between 2019 and 2023 were analyzed. Patients were divided into RUS and AUS groups. AUS procedures were further categorized into single-stage (tubeless) and multi-stage (with protective nephrostomy) subgroups. Technical success, clinical success, complication rates, and etiological data were evaluated and statistically compared.
Results: Technical success was significantly higher in the AUS group (97.6%) compared to the RUS group (37.7%) (p < 0.001). No significant difference was found in clinical success between the groups. AUS maintained high technical success regardless of intrinsic or extrinsic etiology. Although single-stage AUS demonstrated a slightly higher clinical success rate, complication and success rates between single- and multi-stage AUS procedures did not differ significantly. No major complications were observed across the AUS subgroups.
Conclusions: AUS is a highly effective and safe intervention for MUO, outperforming RUS in terms of technical success. When appropriately selected, single-stage AUS offers a less invasive and cost-effective alternative without compromising outcomes. These findings support the broader implementation of single-stage AUS as a first-line option in the management of MUO.
Keywords
Malignant ureteral obstruction, Nephrostomy, Antegrade ureteral stenting, Retrograde ureteral stenting, Single-stage procedure
References
- 1. Kouba E, Wallen EM, Pruthi RS. Management of ureteral obstruction due to advanced malignancy: optimizing therapeutic and palliative outcomes. J Urol. 2008;180(2):444-450. doi:10.1016/j.juro.2008.04.008
- 2. Migita K, Watanabe A, Samma S, Ohyama T, Ishikawa H, Kagebayashi Y. Clinical outcome and management of ureteral obstruction secondary to gastric cancer. World J Surg. 2011;35(5):1035-1041. doi:10.1007/s00268-011-1016-8
- 3. Pradhan TS, Duan H, Katsoulakis E, Salame G, Lee YC, Abulafia O. Hydronephrosis as a prognostic indicator of survival in advanced cervix cancer. Int J Gynecol Cancer. 2011;21(6):1091-1096. doi:10.1097/IGC.0b013e31821cabc8
- 4. Liu KL, Lee BC, Ye JD, Chang YH, Chang CC, Huang KH et al. Comparison of single and tandem ureteral stenting for malignant ureteral obstruction: a prospective study of 104 patients. Eur Radiol. 2019;29(2):628-635. doi:10.1007/s00330-018-5560-6
- 5. Chang SS, Bochner BH, Chou R, Dreicer R, Kamat AM, Lerner SP et al. Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline (published correction appears in J Urol. 2017 Nov;198(5):1175. doi: 10.1016/j.juro.2017.09.002.). J Urol. 2017;198(3):552-559. doi:10.1016/j.juro.2017.04.086
- 6. Hyams ES, Shah O. Malignant extrinsic ureteral obstruction: a survey of urologists and medical oncologists regarding treatment patterns and preferences. Urology. 2008;72(1):51-56. doi:10.1016/j.urology.2008.01.046
- 7. O'Connor EM, Nason GJ, Kiely EA. Urological Management of Extramural Malignant Ureteric Obstruction: A Survey of Irish Urologists. Curr Urol. 2017;11(1):21-25. doi:10.1159/000447190
- 8. Shvero A, Haifler M, Mahmud H, Dotan Z, Winkler H, Kleinmann N. Quality of life with tandem ureteral stents compared to percutaneous nephrostomy for malignant ureteral obstruction. Support Care Cancer. 2022;30(11):9541-9548. doi:10.1007/s00520-022-07354-2
- 9. Ganatra AM, Loughlin KR. The management of malignant ureteral obstruction treated with ureteral stents. J Urol. 2005;174(6):2125-2128. doi:10.1097/01.ju.0000181807.56114.b7
- 10. Kahriman G, Özcan N, Doğan A, İmamoğlu H, Demirtaş A. Percutaneous antegrade ureteral stent placement: single center experience. Diagn Interv Radiol. 2019;25(2):127-133. doi:10.5152/dir.2019.18252